In a pregnant woman, which lipid‑lowering medication is preferred: atorvastatin or ezetimibe?

Neither Atorvastatin nor Ezetimibe is Preferred—Both Should Be Avoided in Pregnancy

In pregnancy, neither atorvastatin nor ezetimibe is the preferred choice; both should be discontinued, and if lipid-lowering therapy is absolutely necessary, bile acid sequestrants (such as cholestyramine) are the only FDA-approved option for use during pregnancy. 1

Guideline-Based Recommendations

The 2020 JACC guidelines explicitly state that statins (including atorvastatin) must be stopped 1-2 months before attempting pregnancy, or immediately upon pregnancy recognition if unplanned 1. This is the standard of care based on longstanding FDA contraindications.

For ezetimibe, the FDA drug label clearly states: "Ezetimibe tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus" 2. This is not an endorsement—it reflects insufficient human safety data. The label notes only animal studies showing skeletal findings at high doses, with no adequate human pregnancy data to establish safety.

The Only Approved Option: Bile Acid Sequestrants

Bile acid sequestrants (cholestyramine, colestimide) are the only lipid-lowering agents approved for use during pregnancy 1. These agents:

• Are not systemically absorbed
• Do not cross the placenta
• Have decades of safety data in pregnancy

However, recent real-world data from a 2026 Czech nationwide study found cholestyramine was associated with significantly higher odds of cesarean section (OR 2.45), preterm delivery (OR 4.78), and low birth weight (OR 3.16) compared to statins or fibrates 3. This suggests even "safe" options carry risks, likely reflecting the underlying maternal disease severity rather than drug toxicity.

Why This Matters: The Evidence on Statins

While statins remain officially contraindicated, emerging evidence challenges this dogma:

• A 2026 Czech study of 1,100 pregnant women found atorvastatin and rosuvastatin had relatively low risk profiles, with ORs for adverse outcomes (cesarean section 1.68-1.96, preterm delivery 1.42-2.58) that were lower than cholestyramine 3
• A 2025 case report described successful use of pravastatin plus PCSK9 inhibitor in a pregnant woman with familial hypercholesterolemia and coronary stenosis, with normal delivery and no fetal abnormalities 4
• A 2022 review noted that recent systematic reviews and meta-analyses suggest statin use "may not be detrimental, and in some selected cases may be beneficial" 5

Clinical Algorithm for Pregnancy

Step 1: Discontinue all statins and ezetimibe immediately upon pregnancy recognition or 1-2 months before planned conception 1

Step 2: Optimize lifestyle management (diet, exercise) as first-line therapy 1

Step 3: If pharmacotherapy is absolutely required (e.g., severe familial hypercholesterolemia with established cardiovascular disease):

• First choice: Bile acid sequestrants (cholestyramine, colestimide) 1
• Consider ezetimibe only if benefits clearly outweigh risks 5—though FDA labeling provides no reassurance of safety 2

Step 4: In extraordinary circumstances (active coronary disease, prior MI, homozygous FH):

• Individualized risk-benefit discussion may justify continuing statins 5, 4
• Pravastatin has the most pregnancy data among statins 1, 4
• This is off-label and requires informed consent

Critical Caveats

• Ezetimibe has no established safety profile in human pregnancy—only animal data showing skeletal abnormalities at high doses 2
• The FDA explicitly states insufficient data exists to evaluate ezetimibe for "drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes" 2
• When ezetimibe is combined with a statin, refer to statin prescribing information—which contraindicate use in pregnancy 2
• Ezetimibe should not be used in nursing mothers unless benefits justify risks 2

Bottom Line

If forced to choose between atorvastatin and ezetimibe in pregnancy, choose neither. Use bile acid sequestrants if lipid-lowering is essential. The question itself reflects a false choice—both agents lack adequate safety data, and guideline-approved alternatives exist 1, 2.